Drug Profile
SLC 0111
Alternative Names: SLC-0111; WBI-5111Latest Information Update: 15 Aug 2023
Price :
$50
*
At a glance
- Originator SignalChem Lifesciences
- Developer SignalChem Lifesciences; Welichem Biotech
- Class Cytostatics; Small molecules
- Mechanism of Action Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 04 Aug 2023 Welichem Biotech and British Columbia Cancer Agency reinitiates a phase Ib clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease) in Canada (PO) (NCT03450018)
- 23 Jun 2022 Welichem Biotech suspends a phase Ib trial in Pancreatic cancer in Canada due to restructuring at the pharmaceutical partner (NCT03450018)
- 29 May 2022 Phase I development in Pancreatic-cancer is ongoing in Canada (NCT03450018)